Accelerate the Clinical Development of Off-The-Shelf Therapies Through Optimal Donor Selection, Novel Gene Engineering and Scalable Manufacture to Achieve Durable, Safe and Accessible Therapies For Patients Globally

Join the Allogeneic Cell Therapies Summit to Transform a Universal Cell Therapy!

Allogeneic therapies are game changing in the field of cell therapy, overcoming current critical barriers around cost, production, and accessibility currently faced with autologous, personalized treatments. With billions of pounds worth of investment seen in collaborations to advance the development of allogeneic CAR-T, NK, macrophage and iPSC-based therapies, the excitement in this space is explosive!

Capitalize on this “holy grail” approach at the 4th Allogeneic Cell Therapies Summit, the leading industry-focused meeting to capture cutting-edge advances across pre-clinical development, translation, manufacturing, supply and storage, to accelerate the successful clinical translation of your allogeneic pipeline.

Join this fast-evolving community to compare and contrast platform technology to improve durability and persistence, review the strategy for selecting gold-standard donor starting material, and learn about the latest developments in gene engineering and serve as the “off-the-shelf” ready-to-use therapeutic agents for large-scale clinical applications.

Over 400 experts from pharma, biotech and leading academia will be uniting in Boston to collaborate and share lessons learned to streamline scalable manufacturing processes, define optimal cryopreservation conditions and define regulatory expectations to achieve the huge demand for these treatments.

Showcasing the work of Allogene, Atara Biotherapeutics, Cellectis, Celularity, ImmunityBio, and more, don’t miss out on the most important meeting of the cell therapy calendar.

What You Can Expect at Allogeneic Cell Therapies Summit 2022:

23378 Allo U.S. Stats